Olmesartan/Hydrochlorothiazide
Brand name: Olmesartan-Hydrochlorothiazide
Rank #497 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$13.9M
Total Cost
246,637
Total Claims
$13.9M
Total Cost
9,410
Prescribers
$56
Cost per Claim
30,154
Beneficiaries
595,185
30-Day Fills
$1,476
Avg Cost/Provider
26
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$13.9M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $13.9M total
Top Prescribers of Olmesartan/Hydrochlorothiazide
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Mohammad Chaudhry | Internal Medicine | Union City, NJ | 318 | $44K |
| 2 | Wilson Antoine | Internal Medicine | Newark, NJ | 186 | $42K |
| 3 | Garo Pehlevanian | Cardiology | Los Angeles, CA | 569 | $27K |
| 4 | Afshine Emrani | Cardiology | Tarzana, CA | 398 | $27K |
| 5 | Aleksandr Zasypkin | Internal Medicine | Brooklyn, NY | 68 | $26K |
| 6 | Alberto Romero | Family Practice | Pasadena, TX | 394 | $25K |
| 7 | Aleksandr Zasypkin | Internal Medicine | Brooklyn, NY | 602 | $24K |
| 8 | Ricardo Rey | Internal Medicine | Clifton, NJ | 219 | $24K |
| 9 | Nina Kushner | Internal Medicine | Brooklyn, NY | 32 | $24K |
| 10 | David Lee | Cardiology | Los Angeles, CA | 313 | $23K |
| 11 | Dina Liberman | Internal Medicine | Brooklyn, NY | 26 | $20K |
| 12 | Jae Yoo | Internal Medicine | Los Angeles, CA | 535 | $20K |
| 13 | Keiichi Kobayashi | Internal Medicine | Honolulu, HI | 155 | $19K |
| 14 | Marcela Marani-Dicovskiy | Internal Medicine | Paterson, NJ | 160 | $19K |
| 15 | Jung Bae | Internal Medicine | Los Angeles, CA | 419 | $19K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 494 | Binimetinib (Mektovi) | $14.1M | 1,094 |
| 495 | Glecaprevir/Pibrentasvir (Mavyret) | $14.1M | 1,011 |
| 496 | Pacritinib Citrate (Vonjo) | $13.9M | 626 |
| 497 | Olmesartan/Hydrochlorothiazide (Olmesartan-Hydrochlorothiazide) | $13.9M | 246,637 |
| 498 | C1 Esterase Inhibitor, Recomb (Ruconest) | $13.8M | 155 |
| 499 | Sildenafil Citrate (Sildenafil Citrate) | $13.8M | 248,961 |
| 500 | Lovastatin (Lovastatin) | $13.6M | 981,262 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology